Based on these results, we further assessed the anticancer effects of C9 and CsA on NSCLC CSCs derived from the EGFR-mutant cells, NCI-H1650 and HCC827, which were more sensitive to C9 and CsA. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.